Sichuan Pengtai Qifan Technology Co., Ltd. – Trademark Portfolio

Entity Type: 99

Sichuan Pengtai Qifan Technology Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include FLORAMEDIS. The owner is based in Chengdu, Sichuan.

Room 4226, 42F, Bldg 1, No. 500, Middle

Section of Tianfu Avenue, Hi-tech Zone,

Chengdu, Sichuan 610041 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Sichuan Pengtai Qifan Technology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Sichuan Pengtai Qifan Technology Co., Ltd. have?

Sichuan Pengtai Qifan Technology Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Sichuan Pengtai Qifan Technology Co., Ltd. file in?

Sichuan Pengtai Qifan Technology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Sichuan Pengtai Qifan Technology Co., Ltd.'s most well-known trademarks?

Sichuan Pengtai Qifan Technology Co., Ltd.'s registered trademark portfolio includes well-known marks such as FLORAMEDIS. These are among 1 currently registered trademark in the portfolio.

What is Sichuan Pengtai Qifan Technology Co., Ltd.'s trademark registration success rate?

Sichuan Pengtai Qifan Technology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.